• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

    2/14/24 4:00:25 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MEIP alert in real time by email
    SC 13G/A 1 z117240sc13ga1.htm AMENDMENT NO. 1

     

     

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G/A

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    MEI Pharma, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.00000002 per share

    (Title of Class of Securities)

     

    55279B301

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      o Rule 13d-1(b)
      x Rule 13d-1(c)
      o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     Page 1 of 8 Pages 
     

     

    CUSIP No. 55279B301

     

     

    13G/A Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    326,084

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    326,084

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    326,084

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    4.9%

     

    12

    type of reporting person

     

    pN

     

     

     Page 2 of 8 Pages 
     

     

     

    CUSIP No. 55279B301

     

     

    13G/A Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    326,084

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    326,084

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    326,084

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    4.9%

     

    12

    type of reporting person

     

    OO

     

     

     Page 3 of 8 Pages 
     

     

     

    CUSIP No. 55279B301

     

     

    13G/A Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Kevin Tang

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) x
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    united states

     

    Number of

    Shares

    BENEFICIALLY

    Owned by

    Each Reporting

    Person with

    5

    Sole Voting Power

     

    0

     

    6

    Shared Voting Power

     

    326,084

     

    7

    Sole Dispositive Power

     

    0

     

    8

    Shared Dispositive Power

     

    326,084

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    326,084

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    4.9%

     

    12

    type of reporting person

     

    IN

     

     

     Page 4 of 8 Pages 
     

     

    Item 1(a).Name of Issuer:

     

    MEI Pharma, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    11455 El Camino Real, Suite 250, San Diego, CA 92130

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.00000002 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 55279B301

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 326,084 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 326,084 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 326,084 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
     

     

    The percentages used herein are based on 6,662,857 shares of Common Stock outstanding as of October 31, 2023, as set forth in the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the Securities and Exchange Commission on November 9, 2023.

     

    (b)       Percent of Class:

     

      Tang Capital Partners 4.9%
      Tang Capital Management 4.9%
      Kevin Tang 4.9%

     

    (c)       Number of shares as to which such person has:

     

    (i)       sole power to vote or to direct the vote:

     

      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin Tang 0 shares

     

    (ii)     shared power to vote or to direct the vote:

     

      Tang Capital Partners 326,084 shares
      Tang Capital Management 326,084 shares
      Kevin Tang 326,084 shares

     

    (iii)     sole power to dispose or to direct the disposition of:

     

      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin Tang 0 shares

     

    (iv)     shared power to dispose or to direct the disposition of:

     

      Tang Capital Partners 326,084 shares
      Tang Capital Management 326,084 shares
      Kevin Tang 326,084 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 Pages 
     

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024    
         
         
    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8

     

     

     

     

     

    Get the next $MEIP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEIP

    DatePrice TargetRatingAnalyst
    7/23/2024Buy → Hold
    Laidlaw
    3/25/2022$4.00 → $1.00Buy → Hold
    Jefferies
    3/25/2022$13.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    3/25/2022$6.00 → $2.00Buy → Hold
    Stifel
    2/3/2022$4.00Buy
    Jefferies
    More analyst ratings

    $MEIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

      SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

      2/14/24 4:00:25 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

      SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

      2/13/24 5:09:37 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

      SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)

      11/1/23 5:20:11 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    SEC Filings

    See more
    • MEI Pharma Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - MEI Pharma, Inc. (0001262104) (Filer)

      3/7/25 4:30:07 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MEI Pharma, Inc. (0001262104) (Filer)

      2/12/25 4:05:08 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by MEI Pharma Inc.

      10-Q - MEI Pharma, Inc. (0001262104) (Filer)

      2/12/25 4:00:20 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Wood Steven D was granted 3,100 shares, increasing direct ownership by 246% to 4,359 units (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      5/21/24 4:00:05 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Flynn James P was granted 7,900 shares (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      5/20/24 4:00:13 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Flynn James P (Amendment)

      4/A - MEI Pharma, Inc. (0001262104) (Issuer)

      1/12/24 4:00:15 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • MEI Pharma downgraded by Laidlaw

      Laidlaw downgraded MEI Pharma from Buy to Hold

      7/23/24 6:35:29 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma downgraded by Jefferies with a new price target

      Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously

      3/25/22 7:17:08 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously

      3/25/22 7:16:36 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MEIP
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $MEIP
    Financials

    Live finance-specific insights

    See more
    • Anson Funds Management Lp bought $329,331 worth of shares (48,060 units at $6.85) (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/25/23 7:43:12 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Funicular Funds, Lp bought $219,554 worth of shares (32,040 units at $6.85) (SEC Form 4)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/25/23 7:41:22 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Anson Funds Management Lp bought $938,226 worth of shares (153,600 units at $6.11)

      4 - MEI Pharma, Inc. (0001262104) (Issuer)

      9/22/23 9:21:02 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

      Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

      2/12/25 4:12:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

      Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

      11/12/24 4:05:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Fiscal Year End 2024 Cash Position

      Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

      9/19/24 4:01:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

      Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

      2/12/25 4:12:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

      Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

      11/12/24 4:05:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Reports Fiscal Year End 2024 Cash Position

      Confirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its fiscal year ended June 30, 2024. Previously on July 22, 2024, the Company announced the commencement of an evaluation of strategic alternatives with the goal of maximizing the value of its assets for its stockholders. Subsequent to that date, the Company announced the engagement of Oppenheimer & Co., Inc. to serve as the Company's exclusive financial adviser to assist in the review and evaluation of that process. As part of the review of strategic alternatives, the Company will consider options such as out-licensing opportunities for existing programs

      9/19/24 4:01:00 PM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MEIP
    Leadership Updates

    Live Leadership Updates

    See more
    • MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl

      6/13/23 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

      MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.

      6/2/23 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

      MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En

      6/22/22 8:00:00 AM ET
      $MEIP
      Biotechnology: Pharmaceutical Preparations
      Health Care